Remepy Secures $36 Million Series A, Propelling Hybrid Drug Innovation
August 16, 2026, 3:35 am
Remepy, a New York biotech, secured $36 million in Series A funding. Total raised hits $62 million. O.G. Venture Partners and M Ventures led the round. Funds drive Hybrid Drug development and Parkinson's program, Hybridopa, into global Phase III trials. The company blends prescription medicines with AI-driven apps. This innovation reshapes patient care. A new era for therapeutic delivery emerges. Remepy leads this charge.
*
Remepy, a pioneering biotechnology firm, recently announced a significant financial milestone. The New York-based company closed a $36 million Series A financing round. This capital infusion accelerates its mission. It propels the development of its revolutionary Hybrid Drugs. This funding brings Remepy's total capital raised to an impressive $62 million.
The Series A round saw strong investor confidence. O.G. Venture Partners and M Ventures co-led the financing. M Ventures is the strategic corporate venture arm of Merck KGaA. Their involvement signals significant industry validation. Additional investors included NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp. This diverse group underscores broad belief in Remepy's vision.
Remepy is carving out a new niche in healthcare. Its focus is Hybrid Drugs. These treatments integrate traditional pharmacology with advanced digital interventions. They are a new class of medicine. They combine prescription drugs with personalized, AI-driven therapeutic applications. This creates a unified "single prescription model." It simplifies treatment. It optimizes patient engagement.
The funds acquired will serve multiple critical objectives. They will accelerate Remepy’s pharmaceutical co-development partnerships. This expands the company's reach. They will also fuel the expansion of its Hybrid Drug pipeline. More indications will benefit from this innovative approach. Crucially, the capital will fund the global Phase III clinical development of Hybridopa.
Hybridopa stands as Remepy's lead program. It targets Parkinson's disease. This debilitating neurological disorder affects millions worldwide. Current therapies manage symptoms. They do not halt disease progression. Hybridopa offers a new treatment paradigm. It combines pharmacological action with adaptive digital support. This dual approach aims for superior outcomes.
The global Phase III trials for Hybridopa are slated to commence in Q4 2026. This marks a pivotal moment for the program. It follows encouraging Phase IIa clinical results. Success in Phase III could bring a transformative option to Parkinson's patients. It promises improved motor function. It offers enhanced quality of life.
The concept of Hybrid Drugs is groundbreaking. Traditional drug development often addresses biological pathways. Digital therapeutics target behavioral and cognitive aspects. Remepy marries these two fields. Its platform allows for comprehensive life cycle management. It enables robust intellectual property generation. It delivers highly personalized, integrative treatments.
This innovation is not limited to Parkinson's disease. Remepy maintains a strategic collaboration with Merck KGaA. This partnership explores Hybrid Drugs across multiple indications. Rare tumors represent a significant starting point. Such collaborations validate Remepy’s platform. They expand its potential impact across diverse medical fields.
The biotechnology landscape constantly evolves. Digital health solutions are gaining immense traction. AI is transforming medical research and patient care. Remepy sits at the intersection of these powerful trends. Its Hybrid Drug platform leverages AI to personalize interventions. It dynamically adapts to individual patient needs. This ensures optimal therapeutic delivery.
Co-CEOs Michal Tsur and Or Shoval lead Remepy. Their vision pushes the boundaries of medicine. They advocate for a more integrated approach to health. Their leadership guides the company's rapid progression. From concept to late-stage clinical trials, Remepy moves with purpose.
The venture capital community recognizes this potential. Investors are increasingly seeking disruptive technologies. Remepy represents a significant investment in future healthcare. Its model could redefine how diseases are treated. It could improve adherence and efficacy. It promises better patient outcomes globally.
The integration of digital and pharmacological components offers unique advantages. Digital interventions can provide real-time feedback. They can monitor patient behavior. They can deliver cognitive exercises or behavioral prompts. This enhances the traditional drug's effect. It makes treatment more comprehensive and adaptive.
For patients, Hybrid Drugs offer convenience. They offer personalized support. The "single prescription model" simplifies access. For healthcare providers, it offers a more holistic tool. It allows for better tracking of patient progress. It enables more informed treatment adjustments.
The market for innovative therapeutic solutions is vast. Chronic diseases demand long-term, integrated care. Neurological disorders present complex challenges. Oncology requires precision and adaptability. Remepy's platform is designed to address these complex needs. It offers tailored, data-driven solutions.
This $36 million funding round is more than just capital. It is a vote of confidence. It signifies belief in Remepy’s scientific rigor. It endorses its commercial strategy. The company is now well-positioned. It will execute its ambitious global development plans.
Remepy is not just developing drugs. It is building a new ecosystem for patient care. Its Hybrid Drug platform aims for transformative impact. It bridges the gap between pill and program. It offers a glimpse into the future of precision medicine. A future where technology and pharmacology unite for healthier lives. The journey continues. The impact grows.
*
Remepy, a pioneering biotechnology firm, recently announced a significant financial milestone. The New York-based company closed a $36 million Series A financing round. This capital infusion accelerates its mission. It propels the development of its revolutionary Hybrid Drugs. This funding brings Remepy's total capital raised to an impressive $62 million.
The Series A round saw strong investor confidence. O.G. Venture Partners and M Ventures co-led the financing. M Ventures is the strategic corporate venture arm of Merck KGaA. Their involvement signals significant industry validation. Additional investors included NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp. This diverse group underscores broad belief in Remepy's vision.
Remepy is carving out a new niche in healthcare. Its focus is Hybrid Drugs. These treatments integrate traditional pharmacology with advanced digital interventions. They are a new class of medicine. They combine prescription drugs with personalized, AI-driven therapeutic applications. This creates a unified "single prescription model." It simplifies treatment. It optimizes patient engagement.
The funds acquired will serve multiple critical objectives. They will accelerate Remepy’s pharmaceutical co-development partnerships. This expands the company's reach. They will also fuel the expansion of its Hybrid Drug pipeline. More indications will benefit from this innovative approach. Crucially, the capital will fund the global Phase III clinical development of Hybridopa.
Hybridopa stands as Remepy's lead program. It targets Parkinson's disease. This debilitating neurological disorder affects millions worldwide. Current therapies manage symptoms. They do not halt disease progression. Hybridopa offers a new treatment paradigm. It combines pharmacological action with adaptive digital support. This dual approach aims for superior outcomes.
The global Phase III trials for Hybridopa are slated to commence in Q4 2026. This marks a pivotal moment for the program. It follows encouraging Phase IIa clinical results. Success in Phase III could bring a transformative option to Parkinson's patients. It promises improved motor function. It offers enhanced quality of life.
The concept of Hybrid Drugs is groundbreaking. Traditional drug development often addresses biological pathways. Digital therapeutics target behavioral and cognitive aspects. Remepy marries these two fields. Its platform allows for comprehensive life cycle management. It enables robust intellectual property generation. It delivers highly personalized, integrative treatments.
This innovation is not limited to Parkinson's disease. Remepy maintains a strategic collaboration with Merck KGaA. This partnership explores Hybrid Drugs across multiple indications. Rare tumors represent a significant starting point. Such collaborations validate Remepy’s platform. They expand its potential impact across diverse medical fields.
The biotechnology landscape constantly evolves. Digital health solutions are gaining immense traction. AI is transforming medical research and patient care. Remepy sits at the intersection of these powerful trends. Its Hybrid Drug platform leverages AI to personalize interventions. It dynamically adapts to individual patient needs. This ensures optimal therapeutic delivery.
Co-CEOs Michal Tsur and Or Shoval lead Remepy. Their vision pushes the boundaries of medicine. They advocate for a more integrated approach to health. Their leadership guides the company's rapid progression. From concept to late-stage clinical trials, Remepy moves with purpose.
The venture capital community recognizes this potential. Investors are increasingly seeking disruptive technologies. Remepy represents a significant investment in future healthcare. Its model could redefine how diseases are treated. It could improve adherence and efficacy. It promises better patient outcomes globally.
The integration of digital and pharmacological components offers unique advantages. Digital interventions can provide real-time feedback. They can monitor patient behavior. They can deliver cognitive exercises or behavioral prompts. This enhances the traditional drug's effect. It makes treatment more comprehensive and adaptive.
For patients, Hybrid Drugs offer convenience. They offer personalized support. The "single prescription model" simplifies access. For healthcare providers, it offers a more holistic tool. It allows for better tracking of patient progress. It enables more informed treatment adjustments.
The market for innovative therapeutic solutions is vast. Chronic diseases demand long-term, integrated care. Neurological disorders present complex challenges. Oncology requires precision and adaptability. Remepy's platform is designed to address these complex needs. It offers tailored, data-driven solutions.
This $36 million funding round is more than just capital. It is a vote of confidence. It signifies belief in Remepy’s scientific rigor. It endorses its commercial strategy. The company is now well-positioned. It will execute its ambitious global development plans.
Remepy is not just developing drugs. It is building a new ecosystem for patient care. Its Hybrid Drug platform aims for transformative impact. It bridges the gap between pill and program. It offers a glimpse into the future of precision medicine. A future where technology and pharmacology unite for healthier lives. The journey continues. The impact grows.